Biotech Investing
Two emerging biotechs just became the most attractive acquisition targets in obesity after releasing game-changing Phase 1 and Phase 2 data on December 8th.
Biotech Investing
Biotech investing looks chaotic from the outside, but retail investors can compete with PhDs by using a disciplined framework, understanding risk, and defining clear exits so they play a game of skill, not luck.
Guide
Standard valuation metrics fail in biotech. Success requires different frameworks. I'll share my approaches—wins, losses, and lessons learned.